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Résumé 
Les cellules endothéliales (CEs) participent au maintien de l’homéostasie vasculaire en 
générant et libérant de nombreux agents bioactifs, incluant l’oxyde nitrique (NO). Le NO 
module plusieurs fonctions vasculaires telles que le tonus et la perméabilité vasculaire via la 
stimulation de la guanylate cyclase soluble (GCs) provoquant la formation de GMPc. D’autre 
part, les phosphodiestérases (PDEs) sont des enzymes métabolisant les nucléotides cycliques 
(GMPc et AMPc) et participent donc à des étapes essentielles du contrôle des voies de 
signalisation du GMPc et de l’AMPc. Bien que les CEs soient la source principale de NO, la 
voie de signalisation NO-GMPc endothéliale et les répercussions fonctionnelles demeurent 
méconnues. Nous avons alors émis l’hypothèse qu’une population spécifique de PDEs ciblant 
le GMPc (PDEs-GMPc) permettrait aux CEs de maintenir des niveaux de GMPc faible malgré 
l’importante production de NO. L’expression des isoformes de PDEs-GMPc dans les artères 
mésentériques de souris fut initialement déterminée. PDE5 et PDE6 furent détectées tant sous 
la forme d’ARNm que de protéines dans les artères natives alors que PDE6 est absente de 
lignées de CEs en culture. La distribution intracellulaire des deux enzymes est distincte. Alors 
que PDE5 est distribué uniformément dans le cytoplasme des cellules endothéliales, les sous-
unités catalytiques de PDE6 (α et β) sont préférentiellement présentes dans la région péri-
nucléaire. Ces résultats suggèrent que PDE6 puisse être impliqué dans le contrôle de 
microdomaines de GMPc. Des simulations effectuées à l’aide d’un modèle mathématique 
développé sur la base de ces données sont en accords avec la notion selon laquelle l’expression 
et la distribution subcellulaire de PDE6 sont responsables de microdomaines de GMPc dans 
l’endothélium. En absence de PDE6, l’ajout de NO sous forme de bolus unique ou répétée 
mène à une augmentation homogène de la concentration cytoplasmique en GMPc malgré la 
présence de PDE5. Toutefois, la présence de PDE6 à la membrane péri-nucléaire crée un espace 
péri-nucléaire pauvre en GMPc. Les résultats de cette étude forment les premières évidences 
de l’expression et de la distribution intracellulaire hétérogène de PDE6 dans les cellules 
endothéliales natives et suggèrent leur implication dans la génération de microdomaines. 
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Abstract 
Endothelial cells (EC) are essential regulator of vascular homeostasis through the generation 
and release of various bioactive agents, including nitric oxide (NO). NO modulates several 
vascular functions such as vascular tone and permeability, through the stimulation of soluble 
guanylate cyclase (sGC) leading to the production of cGMP. Conversely, 
phosphodiesterases (PDEs) are enzymes metabolizing cyclic nucleotides (cGMP and cAMP) 
and are therefore major regulatory players for cGMP and cAMP signalling pathways.  
Although ECs are the main source of NO, little is known on the endothelial NO-cGMP 
signalling pathway and cellular outcomes. It was then hypothesized that a specific population 
of cGMP-phosphodiesterases allows ECs to stabilize cGMP levels despite the elevated 
production of NO. Expression of cGMP-phosphodiesterases was initially studied in resistance 
mesenteric arteries from mice. PDE5 and PDE6 were both found at mRNA and protein levels 
in native arteries but PDE6 is not found in cultured ECs. Interestingly, subcellular distributions 
of both enzymes were distinct. PDE5 appeared to be homogeneously distributed whilst PDE6 
catalytic subunits (PDE6α and PDE6β) showed a preferential staining in the perinuclear 
region. These results suggest that PDE6 might be involved in the regulation of cGMP 
microdomains. Based on these findings, a mathematical model was developed. Simulations of 
dynamic cGMP levels in ECs support the notion of cGMP microdomains dependent on PDE6 
expression and localization. In the absence of PDE6, application of NO either as a single bolus 
or repetitive pulses led to a homogeneous increase in cGMP levels in ECs despite PDE5 
homogeneous distribution. However, PDE6 subcellular targeting to the perinuclear membrane 
generated a cGMP-depleted perinuclear space. The findings from this study provide the first 
evidence of the expression and specific intracellular distribution of PDE6 in native endothelial 
cells that strongly support their involvement in the generation of cGMP microdomains. 
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Chapter 1: Introduction 
1. Blood vessels 
The cardiovascular network can be divided into three main types of blood vessels: arteries, 
veins and capillaries. They are the conduits through which the blood is delivered to organs and 
allow an appropriate supply of oxygenated blood and nutrients. It further washes out the 
metabolic end products. As a closed system, the three blood vessel types are connected to each 
other in the following order, starting from the heart, arteries, capillaries and veins. Altogether, 
the different parts of the vascular network work in collaboration to ensure proper perfusion of 
the entire body. But the role of each type of vessel is different and is matched by a distinct 
structure that even varies within a vessel type. 
1.1 Structure 
The structure of blood vessel walls can be divided into three layers (from the outside to the 
lumen): tunica adventitia (or externa), tunica media and tunica intima. The tunica adventitia is 
constituted of connective tissue and collagen fibers conferring elasticity and compliance to the 
blood vessel. The tunica media is mainly populated by smooth muscle fibers that actively 
regulate blood vessel diameter. The tunica intima is a single sheet of endothelial cells covering 
the inside of the blood vessels. The endothelial cells are separated from the smooth muscle 
cells by an internal elastic membrane (Fig. 1.1). Although they share the same general structure 
as detailed above, arteries are different from the veins. For example, arteries have a thicker 
media layer which is due to their specific function. 
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Figure.1.1 Structure of blood vessels. Blood vessels are constituted of three layers: tunica 
adventitia (externa), tunica media and tunica intima (adapted from 
https://classconnection.s3.amazonaws.com)  
 
1.1.1 Smooth muscle cells 
Vascular smooth muscle cells (VSMCs) are the main constituent of the arteries and are 
responsible for the tone and the active control of vessel diameter. They are aligned 
perpendicularly to the vessel orientation and surround the endothelial cells. Communication 
between endothelium and smooth muscle cells occurs through a structure called 
myoendothelial projection (MEP) which is important for ECs-VSMCs communication  (Moore 
& Ruska, 1957).  
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1.1.1.1 Structure 
VSMC is non-striated, spindle shape mononucleated myocyte with a diameter ranging from  2 
to 10 µm (Panner & Honig, 1967). The contractile apparatus is made of three filament types: 
the long myosin filaments, actin filaments, and filaments of intermediate size that contain two 
specific proteins, desmin and vimentin (Panner & Honig, 1967). Unlike skeletal and cardiac 
muscles, smooth muscle cells contain no myofibrils or sarcomeres. Smooth muscle cells 
communicated with each other via gap junctions that electrically couple the cells. They make 
a low resistance pathway allowing rapid spread of electrical signals.  
1.1.1.2 Function 
The role of VSMCs is not limited to contraction since they also have the capacity to proliferate, 
migrate, synthesize materials composing extracellular matrix (ECM) components, and secrete 
cytokines and growth factors. These functions make VSMCs a regulator of vascular 
homeostasis that goes beyond the control of vessel diameter. For acute and appropriate blood 
redistribution within the body, the local blood perfusion is regulated by diameter of blood 
vessels and is dependent on relaxation and contraction of VSMCs.  
Calcium required for contraction comes mostly from voltage-dependent calcium channels at 
the plasma membrane and to a lower extent from the sarcoplasmic reticulum (Fig. 2). When 
intracellular calcium level increases, Ca2+ ions bind to calmodulin (CaM) and the Ca2+/CaM 
complex activates myosin light chain kinase (MLCK), which then phosphorylates myosin. 
Phosphorylated myosin binds actin filaments to initiate cross bridge cycling and contraction. 
Myosin dephosphorylation occurs when cytoplasmic Ca2+ levels lower and this result in 
detachment of myosin heads from actin (myocyte relaxation).      
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Figure.1.2 Smooth muscle contraction: Increase in intracellular Ca2+ levels will provoke 
smooth muscle contraction. The main source of Ca2+ contributing to contraction originates 
from extracellular space. ROC: receptor-operated channels, VOC: voltage-operated channels, 
VDCC: voltage-dependent calcium channels, SR: sarcoplasmic reticulum, IP3P: Inositol 
trisphosphate receptor, RyR: Ryanodine receptors, ADP: Adenosine diphosphate, ATP: 
Adenosine triphosphate, MLC: Myosin light chain, MLCK: myosin light chain kinase, MLCP: 
Myosin light chain phosphatase (adapted from Zhao et al., 2015). 
 
1.1.2 Endothelial cells 
1.1.2.1 Structure 
The endothelium was initially characterized as an inert cellophane-like membrane lining the 
cardiovascular system until the 1800s, when von Reckingausen determined that vessels are 
lined by a monolayer of cells called endothelial cells (ECs). ECs line the entire vascular system 
and they are connected to each other by various types of adhesive structures and cell-to-cell 
junctions (Cines et al., 1998). 
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1.1.2.2 Function 
The primary function of ECs is to maintain vascular homeostasis through the generation and 
release of a wide range of factors in response to chemical and physical signals. These factors, 
molecules or mechanisms, allow the endothelium to regulate vascular tone, thrombosis, 
vascular inflammation, smooth muscle cell proliferation and cellular adhesion. 
1) Blood vessel formation 
Development of vascular networks is coordinated by ECs through the release of growth factors 
such as vascular endothelium growth factor (VEGF) that initiates vasculogenesis or angiogenic 
sprouting and leads to formation of immature vessels. Other families of growth factors like 
angiopoietins (Ang) and ephrin are important for blood vessels formation, remodelling and 
maturation. For example, Ang1 is an important molecule that maintains the stability of the 
mature vessels (Gale & Yancopoulos, 1999; Yancopoulos et al., 2000). Indeed, embryos 
lacking Ang1 or Tie2, the main receptor for Ang, develop a normal primary vasculature but it 
fails to undergo any further remodelling. On the other hand, mouse embryos lacking VEGF fail 
to develop a normal primary vasculature (Suri et al., 1996). 
2) Coagulation and fibrinolysis 
In physiological conditions, the endothelium is both antithrombotic and anticoagulant because 
it secretes several molecules needed for regulation of platelet functions and blood coagulation. 
Endothelial damage or pro-inflammatory stimuli would alter the capacity of the endothelium 
to maintain this antithrombotic capability (Cines et al., 1998). 
Nitric oxide (NO) and prostacyclin (PGI2) are the main antiplatelet agents secreted by ECs 
(Cines et al., 1998). They increase cyclic nucleotide levels in platelets, preventing their 
aggregation (de Graaf et al., 1992). Stimulation of ECs with bradykinin, thrombin or ATP will 
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results in an increased production of NO and PGI2, and inhibition of thrombi formation. 
However, NO and PGI2 are not the only mechanisms involved in endothelial regulation of 
coagulation. A more detailed review of the mechanisms have been documented elsewhere 
(Michiels, 2003). 
3) Endothelial cell barrier 
The endothelium is also a selective barrier allowing a discrete transport of molecules between 
tissues and blood (Pries et al., 2000). This barrier property is conferred by three types of 
junctions which are morphologically and functionally different: adherens junctions, tight 
junctions, and gap junctions (Dejana et al., 1995). Adherens junctions are made of cadherins 
anchored to a network of intracellular cytoplasmic proteins named catenins (Dejana, 1996). 
Tight junctions connecting ECs are responsible for tight sealing property of the endothelium. 
These junctions juxtaposes plasma membrane of attached cells through association of occludins 
that are connected to several cytosolic proteins such as ZO-1, ZO-2 and cingulin  (Bazzoni et 
al., 1999). 
4) Vascular tone 
ECs are essentially recognized as the major regulator of vascular tone. They can finely tune 
vascular diameter via the generation and release of several vasodilatory or vasocontractile 
agents that command contractile status of VSMCs. The delicate equilibrium between these two 
classes of mechanisms is dependent on the endothelial health as endothelial dysfunction is 
associated with an impaired endothelial-dependent vasodilation and increased endothelium-
associated vasoconstriction. 
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A) Vasodilation 
The most potent endothelial-derived relaxing factor is nitric oxide (NO), a free radical gaseous 
molecule (Palmer et al., 1987), was also the first endothelial modulator identified. Several 
agonists such as acetylcholine, bradykinin, histamine or adenosine stimulate endothelial 
production of NO (Govers & Rabelink, 2001). Shear stress, the force evoked by blood flow on 
endothelium, can also increase endothelial NO production through upregulation of endothelial 
nitric oxide synthase (eNOS) gene expression and eNOS activation (Govers & Rabelink, 2001). 
In addition to its impact on vascular myocyte tone, NO inhibits coagulation and smooth muscle 
cell proliferation (Xiao et al ., 1997).  
NO is not the only endothelial-derived vasorelaxant. PGI2 is also an important vasodilator, 
which acts through the activation of smooth muscle adenylate cyclase and generation of cAMP. 
ECs also generate EDHF (Endothelium-dependent hyperpolarizing factor), a non-NO/PGI2 
factor that induces a smooth muscle hyperpolarization and lead to myocyte relaxation. EDHF 
consists of an amalgam of different molecules (EETs, H2O2) or mechanisms (K+ clouds, 
KCa2.x/KCa3.1 channels) that evoke smooth muscle hyperpolarization (Félétou, 2011).  
B) Vasoconstriction 
ECs also generate and release vasoconstrictive factors such as endothelin-1, thromboxane A2 
and angiotensin II (Furchgott & Vanhoutte, 1989). It is important to note that angiotensin II is 
not generated by endothelial cells per se but an enzyme, the Angiotensin converting enzyme 
(ACE) at the endothelial membrane cleaves circulating angiotensin I into angiotensin II.  
5) Inflammation 
Inflammation is a protective process involving a series of mechanisms where endothelial cells 
play a key role. However, inflammation can become deleterious if excessive or chronic as it 
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could lead to increased vascular permeability and thus results in exaggerated fluids exudation 
and leukocytes migration (Muller, 2003). Endothelial adhesion molecules play major roles in 
the different steps of leukocyte extravasation including activation, rolling, adhesion and trans-
endothelial migration (Allport et al., 1997).  
1.1.3. Endothelial-smooth muscle communication: Myoendothelial Junction (MEJ) 
The endothelium is physically isolated from the underlying smooth muscle cells by the internal 
elastic laminae (IEL). This structure, made of collagen and elastin, is too thick to allow 
endothelium-myocyte contacts and intercellular interactions. However, the IEL is not 
continuous and fenestrations of the IEL allow formation of structures called myoendothelial 
projections (MEP). MEPs, found in resistance arteries, are cellular extensions through IEL 
fenestrations where close apposition of endothelial and smooth muscle membranes occur 
(myoendothelial junctions; MEJ) (Moore & Ruska, 1957; Heberlein et al., 2009). ECs-VSMCs 
communication through these MEPs allows bi-directional signaling to accurately modulate 
vessel diameter. Interestingly, the number of MEJs and gap junction channels increase in distal 
arteries, where the endothelial-derived hyperpolarizing factor (EDHF) is elevated, while it is 
less frequent in proximal arteries (Sandow & Hill, 2000;  Straub et al., 2011). Indeed, MEPs 
are considered as a nexus of EC-VSMC communication pathways aiming to finely coordinate 
vascular tone. MEPs are enriched in endoplasmic reticulum (ER) (Isakson et al., 2007), 
caveolae (Straub et al., 2011; Saliez et al., 2008), cytosketetal components (Isakson et al., 2008) 
and ion channels (Ledoux et al., 2008). The presence of cytoskeletal components (actin and 
microtubules) within MEPs (Isakson et al., 2008) suggests that these structures are dynamic 
and could support protein trafficking (Straub et al., 2014). 
Gap junctions are communication pathways between ECs and VSMCs where second 
messengers, ions, charges, and small metabolites can freely move between the two adjacent 
cells (Brisset et al., 2009; Straub et al., 2014). Electrical propagation secondary to changes in 
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membrane potential can occurs through gap junctions (Saez et al., 2003). Structurally, gap 
junction channels are made of six connexins (Cx) subunits connecting the cytoplasm of 
adjacent cells (Saez et al., 2003). Cx37, Cx40, Cx43, and Cx45 are the only connexins reported 
in the vascular wall (Yeh et al., 1997) and their expression varies according to the vascular bed 
and species studied. However, only Cx37, Cx40, and Cx43 were found in the MEJ (Isakson et 
al., 2008). 
The presence of ER at the MEP is supportive of a unique and spatially restricted Ca2+ signalling 
pathway (Isakson et al., 2007). Indeed, calcium pulsars are repetitive Ca2+ release events that 
are restricted to endothelial MEP. Specific localization of Ca2+ pulsars is due to presence of 
IP3R-dense ER stores and leads to specific activation of adjacent KCa3.1 channels within 
endothelial MEP. The hyperpolarization thus generated provokes myocyte relaxation (Ledoux 
et al., 2008) (Fig. 1.3). 
 
1.1 Regulation of blood vessel diameter  
Vascular tone and arterial diameter is essentially dependent on VSMCs contractile status. Ca2+ 
entry through voltage-dependent Ca2+ channels being the main source of Ca2+ to produce 
contraction, modulation of vascular tone will preferentially target opening of these Ca2+ 
channels via changes in membrane potential. Indeed, depolarization of myocyte membrane will 
provoke Ca2+ channel opening, allowing Ca2+ influx and increase in cytoplasmic Ca2+ levels 
and thereby ensure contraction. Conversely, hyperpolarization of VSMCs membrane will 
decrease the open probability of voltage-dependent Ca2+ channels and thus lead to relaxation. 
Cyclic nucleotides (cAMP and cGMP) are involved in signalling pathways regulating myocyte 
contraction. 
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Figure 1.3 Endothelial calcium pulsars: Localized Ca2+ release mediated by IP3 receptors 
within MEPs activates KCa3.1 channels and lead to smooth muscle hyperpolarization and 
relaxation. IEL: Internal elastic lamina, IP3R: Inositol triphosphate receptors, VDCC: Voltage-
dependent calcium channels, RyR: Ryanodine receptors, ER: endoplasmic reticulum (adapted 
from Ledoux et al., 2008) 
 
1.2.1 cAMP-dependent vasodilation 
Adenylate cyclase activation evoked by PGI2 binding to its receptor will induce an increase in 
cAMP levels and activation of cAMP-dependent protein kinase (Protein Kinase A; PKA). PKA 
phosphorylation is associated with a decrease in cytoplasmic Ca2+ levels via several 
mechanisms including an increase in SERCA (Sarco/endoplasmic reticulum calcium ATPase) 
pump activity, a lower MLCK activity and hyperpolarization of VSMCs membrane (Morgado 
et al., 2012; Adelstein et al., 1978). 
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1.2.2 cGMP-dependent vasodilation 
In parallel to the cAMP-PKA pathway, a cGMP-centric signalling pathway is also found in 
VSMCs. In this case, protein kinase G (PKG) is the main effector of the cGMP pathway. An 
increase in cGMP levels activates PKG, which in turn promotes VSMCs relaxtion through 
various mechanisms, including phosphorylation of K+ channels and hyperpolarization of the 
myocyte. It also stimulates Ca2+ extrusion from the cytoplasm through enhanced pumping in 
the SR (Morgado et al., 2012). 
1.3 NO-cGMP-PKG pathway  
1.3.1 Nitric oxide synthase (NOS) 
Initial compoenent of the NO-cGMP-PKG pathway, NOS are heme-containing enzymes that 
catalyze the NADPH- and O2-dependent oxidation of L-arginine to nitric oxide (NO) and 
citrulline. Initially identified and described in 1989 (Bredt & Snyder, 1990; Alderton et al., 
2001), homodimeric NOS are generally considered as the physiologically functional form of 
the enzyme (Hevel et al., 1991; Alderton et al., 2001).  
1.3.1.1 Classification of Nitric oxide synthetase (NOS) 
Three isoforms of NOS have been identified: NOS I, II and III. The neuronal isoform (nNOS, 
NOS I) is mainly found in neurons. NO produced in neurons acts as a neuronal messenger 
modulating synaptic neurotransmission (Michel & Feron, 1997; Prast & Philippu, 2001). On 
the other hand, the inducible NOS isoform (iNOS, NOS II) is expressed in cells in response to 
inflammatory mediators (Michel & Feron, 1997). The main source of NO within vessel walls 
is the endothelial isoform of NOS (eNOS, NOSIII), which is constitutively expressed in ECs 
(Palmer et al., 1988)  (Sandoo et al., 2010). Although NOS isoforms differ in their function, 
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tissue localization and regulation, they share a common structure and catalytic mechanism 
(McMillan et al., 1992). 
1.3.1.2 eNOS activation 
When located in caveolae, eNOS is found as monomer and is inactive. Once intracellular Ca2+ 
increases, eNOS unbind caveolin-1 and homodimerizes to become active (Bucci et al., 2000). 
Endothelial agonists like acetylcholine, bradykinin, substance P and shear stress can induce 
intracellular Ca2+ increase and NO production through activated eNOS (Michel & Feron, 1997; 
Bae et al., 2003). Moreover, shear stress can also upregulate eNOS expression (Alderton et al., 
2001). In addition to intracellular Ca2+, phosphorylation of eNOS has been shown to modulate 
eNOS activity. For example, phosphorylation of Thr495 inhibits the enzyme while 
phosphorylation at Ser1177 and Ser633 stimulate NO production (Alderton et al., 2001). The 
important literature on eNOS illustrates the significant impact of the enzyme on vascular tone. 
1.3.2 Nitric oxide (NO) 
1.3.2.1 Nitric oxide as a signalling molecule 
As expressed previously, eNOS is highly expressed in ECs and is the main source of NO found 
in plasma (Walter & Gambaryan, 2009). NO is a colorless, inorganic gas, dissolvable in water 
and lipids (Knowles & Moncada, 1994; Garthwaite & Boulton, 1995). This latter property is 
crucial to the signaling molecule as it conveys an elevated diffusibility and allows the molecule 
to act on neighboring VSMCs. However, the half-life of NO is very short (approximately 5-6 
seconds) (Garthwaite & Boulton, 1995). The main target of NO is the soluble guanylate cyclase 
(sGC). Indeed, within the nanomolar range, NO binds a prosthetic heme on the β-subunit of 
sGC which results in a 100- to 200-fold increase in the enzyme activity (Ignarro et al., 1982). 
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However, despite the massive production of NO by ECs, NO-cGMP pathway in ECs remains 
poorly understood.   
1.3.2.2 Cardiovascular effects of NO 
As a multipotent molecule, NO modulates many cardiovascular processes such as vascular 
tone, myocardial functions, and platelet aggregation (Forstermann & Sessa, 2012 ; Bryan et al., 
2009 ; Schafer et al., 1980). Alteration in NO bioavailability (either decreased production or 
increased degradation) would result in higher vascular tone, decreased vessel lumen and 
elevated blood pressure. Moreover, insufficient NO is also associated with VSMCs 
proliferation as NO, under normal conditions, supresses VSMC proliferation (Ignaro et al, 
2001). NO also increases cGMP through activation of cGC, leading to PKG activation and 
phosphorylation of various targets, including ion channels resulting in smooth muscle 
relaxation (Bryan et al., 2009). Modulation of vascular tone is not the only process involving 
enhanced cGMP production as NO supresses thromboxane A2-induced platelets aggregation 
in a cGMP-dependent manner (Schafer et al., 1980; Wang et al., 1998).  
Additionnally, NO decreases monocytes adhesion to endothelium and therein minimizes 
monocyte exudation and initiation of atherosclerotic plaque (Tsao et al., 1997). Moreover, 
antioxidant properties of NO make the endothelium-derived molecule an excellent 
atheroprotective agent. Indeed, NO inhibits oxidation of LDL cholesterol, the critical step in 
atherosclerosis (Hogg et al., 1993). Furthermore, NO stimulates growth hormone production 
(Rubinek et al., 2005) 
The brief half-life of NO is not the only limiting factor to NO-dependent outcomes. NO rapidly 
bind to oxy- and deoxyhemoglobin (Hb) (Lancaster, 1994) that are abundant in erythrocytes, 
suggesting that a significant portion of endothelium-derived NO is scavenged in blood. 
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However, in physiological conditions, NO production is sufficient to adequately modulate 
smooth muscle cells function (Lancaster, 1994).  
1.3.3 Guanylate cyclases  
Two isoforms of guanylate cyclase, enzyme generating cGMP, have been characterized, the 
soluble (sGC) and the particulate guanylate cyclase (pGC). Essentially, pGC is a plasma 
membrane receptor activated by natriuretic peptides whilst sGC is a cytosolic enzyme activated 
by NO, but also by carbon monoxide (CO) (Sharina et al., 2012; Lukowski et al., 2014). 
Application of NO donors rapidly elevates cytoplasmic cGMP level. Actually, cGMP levels 
peaks within ∼50s following application of NO donors to VSMCs (Wyatt et al., 1998). 
Although sGC is highly expressed in VSMCs, the enzyme has also been found in ECs. 
However, limited information is currently available on sGC-cGMP functions in ECs. Recent 
work showed that cGMP levels modulate endothelial permeability and binding/activation of 
immune cells to endothelium (Ahluwalia et al., 2004). 
1.3.4 cGMP 
Upon NO binding, sGC converts guanosine triphosphate (GTP) into cyclic guanosine 
monophosphate (Guanosine 3', 5’-cyclic phosphate; cGMP), an essential activator of PKG 
(Fig.1.4). Conversely, cGMP is hydrolyzed in GMP by phosphodiesterases (PDEs), a class of 
enzymes that metabolizes cyclic nucleotides (cAMP and cGMP) by degradation of 3`-
phosphodiester bond (Fig.1.4). In recent times, PDEs have gained interest as potential 
therapeutic avenues for treatment of pathologies associated with decreased cAMP/cGMP 
levels. Indeed, the balance between the activity of sGC and PDEs is the primary determinant 
of intracellular cGMP levels (Francis et., 2010). 
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Intracellular cGMP levels is probably not homogeneous throughout cellular cytoplasm since 
several players in cGMP synthesis/degradation are heterogeneously distributed and thus 
creating pools of cGMP (cGMP microdomains) in discrete cellular regions (Fischmeister et al., 
2006). However, global arterial cGMP level is generally around ∼0.1 μM in resting conditions 
(Francis et al., 2010). 
 
 
 
Figure 1.4 – Structure of guanosine 3', 5’-cyclic phosphate (cGMP) (adapted from 
http://pubchem.ncbi.nlm.nih.gov) 
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1.3.5 PKG 
PKG is a serine-threonine kinase activated by cGMP. Binding of cGMP to the allosteric domain 
of PKG enhances phosphorylation activity by 3 to 10-Fold (Francis & Corbin, 1999; 
Schlossmann & Desch, 2009). Three mammalian PKG isoforms have been reported, PKGIα, 
PKGIβ and PKGIIα. PKGIα is the predominant isoform expressed in endothelial cells 
(Lukowski et al., 2014; Kalderon & Rubin, 1989). 
1.3.6 Phosphodiesterases 
PDEs play a critical role in intracellular signaling pathway involving cyclic nucleotides via 
hydrolyzation of cAMP and cGMP and thus negatively regulate associated proteins and 
transcription factors (Keravis & Lugnier, 2012). According to their high catalytic efficiency, 
they are indeed considered as the main determinant of cyclic nucleotide-dependent pathways. 
Mammalian PDEs have been classified in eleven families (Table 1) mainly based on 
cAMP/cGMP affinity, regulation, structural similarities, tissue distribution and 
pharmacological properties (Bender & Beavo, 2006; Lugnier, 2006). Some PDEs, such as 
PDE3, show higher affinity to cAMP, while some, such as PDE5 and PDE6, have higher 
affinity to cGMP. Nevertheless, PDE1C, PDE2A and PDE11A have a similar affinity to both 
substrates (Table 1). From a structural perspective, PDEs are found in dimers. Each monomer 
has three distinct domains, a N-terminal regulatory domain, a catalytic domain, and a C-
terminal domain (Keravis & Lugnier, 2012).  PDEs regulation is not limited to binding of cyclic 
nucleotides, but is rather comprehensive including phosphorylation steps, anchoring proteins, 
subcellular targeting and translocation, etc. (Bender & Beavo, 2006; Lugnier, 2006; Francis et 
al., 2010). 
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The intracellular localization of PDE isoforms as well as their tissue distribution is different 
(Table. 2) and the physiological impact of PDEs varies accordingly. For example, PDE3B is 
highly expressed in hepatocytes where it modulates insulin signaling (Bender & Beavo, 2006). 
As mentioned above, cyclic nucleotide affinity varies amongst PDE family members, with 
PDE1A and B, PDE5, PDE6 and PDE9 showing a higher cGMP/cAMP affinity ratio (Table. 
1). PDE1 and PDE9 are predominantly expressed in neuronal and vascular smooth muscle cells 
but have been found in other cell types (Table. 2). However, PDE1 and PDE9 sensitivity to 
cGMP is lower than PDE5 and PDE6 (Table. 1). PDE6 expression is mostly restricted to retina 
while PDE5 is expressed in multiple tissues, including vascular cells (Table 2).  
Cellular outcomes of PDE activity are also diversified (Table. 3) as evidenced by the multiple 
pathologies associated with altered PDE function. Bronchial asthma, erectile dysfunction, 
hypertension, heart failure, schizophrenia are example of such diseases (Barnett & Machado, 
2006; Carson, 2007; Coward & Carson, 2008; Dorsey et al., 2010; Francis, Corbin, & Bischoff, 
2009; Galie et al., 2009; Galie et al., 2005; Mebazaa et al., 2010; Rubio-Aurioles et al., 2009; 
Stehlik & Movsesian, 2009). Actually, therapeutic approaches targeting PDEs are already used 
in treatment of pathologies like autoimmune and inflammatory diseases (Francis et al., 2010). 
The most famous is undoubtedly the inhibition of PDE5 for the treatment of erectile 
dysfunction but PDE5 inhibitors are now also used to treat pulmonary hypertension (Francis et 
al., 2010). 
Compartmentalization of the substrate, cGMP, has been reported in different types of cells. 
Such studies used natriuretic peptides to activate pGC or NO donors to activate sGC. However, 
studies on subcellular targeting of PDEs revealed that cGMP-specific PDEs play a fundamental 
role in creation of the specific intracellular patterns of cGMP. For example, in VSMC, cGMP 
synthesis induced by atrial natriuretic peptide (ANP) is spatially confined to the subplasma 
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membrane space, while this spatial localization is lost in the presence of a PDE5 inhibitor, 
(Nauch et al., 2008).  
Table 1. PDE enzymes kinetic properties (adapted from Bender & Beavo, 2006). 
Isoform Substrate 
specificity Km  
   Vmax  
  cGMP cAMP cGMP cAMP 
              μM    μmol / min / mg  
PDE1A 
 
cAMP<cGMP 2.6—3.5 72.7—124 50—300 70—450 
PDE1B 
 
cAMP<cGMP 1.2—5.9 10—24 30 10 
PDE1C 
 
cAMP=cGMP 0.6—2.2 0.3—1.1 — — 
PDE2A 
 
cAMP=cGMP 10 30 123 120 
PDE3A 
 
cAMP>cGMP 0.02—0.15 0.18 0.34 3.0—6 
PDE3B 
 
cAMP>cGMP 0.28 0.38 2.0 .5 
PDE4A 
 
cAMP>cGMP — 2.9—10 — 0.58 
PDE4B 
 
cAMP>cGMP — 1.5—4.7 — 0.13 
PDE4C 
 
cAMP>cGMP — 1.7 — 0.31 
PDE4D 
 
cAMP>cGMP — 1.2—5.9 — 0.03—1.56 
PDE5A 
 
cGMP>cAMP 2.9—6.2 290 1.3 1.0 
PDE6A/B 
 
cGMP>cAMP 15 700 2300 — 
PDE6C 
 
cGMP>cAMP 17 610 1400 — 
PDE7A 
 
cAMP>cGMP — 0.1—0.2 — — 
PDE7B 
 
cAMP>cGMP — 0.03—0.07 — — 
PDE8A 
 
cAMP>cGMP — 0.06 — — 
PDE8B 
 
cAMP>cGMP — 0.10 — — 
PDE9A 
 
cGMP>cAMP 0.70—0.17 230 — — 
PDE10A 
 
cAMP<cGMP 13—14 0.22—1.1 — — 
PDE11A 
 
cAMP=cGMP 0.95—2.1 2.0—3.2 — — 
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Table.2 The localization of PDE families (adapted from Bender and Beavo, 2006) 
Isoform                                                        Localization  
              Tissue/Cellular Intracellular 
PDE1A Smooth muscle, sperm; PDE1A1 in heart and 
lung, PDE1A2 in brain 
Predominantly cytosolic 
PDE1B PDE1B1 in smooth muscle cells, lymphocytes, 
and neurons; PDE1B2 in lymphocyte and 
macrophages. 
Cytosolic 
PDE1C Brain, smooth muscle, spermatids; PDE1C2 in 
olfactory epithelium 
Cytosolic 
PDE2A Brain, adrenal medulla heart, macrophage 
subsets, platelets, endothelial cell subsets. 
PDE2A3 and PDE2A2 are membrane-
bound, but PDE2A1 is cytosolic 
PDE3A Vascular smooth muscle, heart, platelets, kidney 
and oocyte. 
Membrane-associated or cytosolic. 
PDE3B Vascular smooth muscle, hepatocyte, 
adipocytes, kidney, sperm, β cells, macrophages 
and T lymphocytes. 
Predominantly membrane-associated; 
Localized to microsomal fractions and 
endoplasmic reticulum. 
PDE4A Olfactory system, brain, immune cells, and 
testis.  
PDE4A5 restricted to membrane 
ruffles through its Src homology 
domain; PDE4A1 is membrane-
associated; PDE4A4 associates with 
Src family kinases. 
PDE4B Variable tissues, notably in brain and immune 
cells. 
PDE4s are recruited to interact with β –
arrestin.     
PDE4C PDE4 isoform that has the least expression; 
found in lung, neurons and testis. 
Predominantly cytosolic. 
PDE4D Widely expressed but mainly in brain tissue.   Cytosolic or particulate fractions.  
PDE5A Vascular smooth muscle, platelets, brain, heart, 
lungs and kidney; PDE5A1 and PDE5A2 are 
widely distributed, PDE5A3 is specific to 
vascular smooth muscle 
Cytosolic 
PDE6A/ 
PDE6B 
Rod cells of the photoreceptors and pineal gland Targeted to the membrane by 
isoprenylation; its association with the 
δ subunit results in cytosolic 
localization 
PDE6C Cone cells of the photoreceptor and pineal gland Cytosolic by virtue of its association 
with the δ subunit 
PDE7A Skeletal muscle, endothelial cells; PDE7A1was 
found in immune cells, PDE7A2 in heart. 
Cytosolic. 
PDE7B Heart, brain, liver, pancreas, skeletal muscle and 
testis.   
Cytosolic 
PDE8A Testis, small intestine, spleen, colon, ovary and 
kidney.    
Cytosolic and particulate fractions 
PDE8B PDE8B1 is expressed in thyroid, PDE8B3 and 
PDE8B2 are expressed in brain and thyroid 
Cytosolic and particulate fractions 
PDE9A Kidney, spleen, brain, gastrointestinal tissues, 
and prostate.   
PDE9A5 is cytosolic, whereas 
PDE9A1 is localized in nucleus 
PDE10A Brain, heart, testis, and thyroid; also found in 
pituitary gland and cardiac and skeletal muscle.   
PDE10A1 and PDE10A3 are cytosolic, 
while PDE10A2 is particulate. 
PDE11A Skeletal muscle, testis, prostate, salivary gland, 
liver and thyroid gland.  
Cytosolic 
 
20 
 
Table.3 The role of PDE families in physiological processes (adapted from Bender & Beavo, 
2006). 
Isoform                                                             Role 
PDE1 PDE1A regulate vascular smooth muscle contraction and sperm function; PDE1B is involved 
immune cells activation and in dopaminergic signaling; PDE1C is needed for the proliferation of 
vascular smooth muscle cell, neuronal signalling and sperm function. 
PDE2 PDE2 regulates both cGMP and cAMP pathways; it controls aldosterone secretion, barrier role 
of endothelial cells in case of inflammation, cAMP and PKA phosphorylation of Ca+2channels in 
the heart, long term memory and cGMP in neurons.   
PDE3 PDE3A regulates platelet aggregation, cardiac contractility, vasoconstriction, renin release and 
oocyte maturation; PDE3B mediates insulin signaling and mediates the inhibitory action of leptin 
as well as regulates cell cycle/proliferation.   
PDE4 PDE4 has role in brain function, activation of immune cells, neutrophil infiltration, and 
proliferation of vascular smooth muscle, cardiac contractility, vasodilation and fertility. 
PDE5 PDE5 regulates vascular smooth muscle contraction, especially in lung and penis and lung ; it is 
a main component of NO-cGMP signaling in platelets to regulate its aggregation. It plays a role 
in regulation of cGMP signaling in the brain 
PDE6 PDE6 is involved in the photoresponse  (signal transduction) as well as melatonin release from 
the pineal gland 
PDE7 PDE7 plays a role in activation of T-cell and other inflammatory cells 
PDE8 PDE8 has a role in T cell activation, leydig cell, or sperm function 
PDE9 The function of PDE9 is unknown, but it is thought to regulate NO-cGMP signaling in the brain 
PDE10 PDE10A may regulate cGMP in the brain and thought to has a role in learning and memory 
PDE11 PDE11 has a role in sperm function and development  
 
1.3.6.1 PDE5 
PDE5 is the most extensively studied cGMP-specific PDE in both animals and human because 
of its critical role in the cardiovascular system. PDE5 is therefore well characterized on a 
structural/function perspective but is also granted with an interesting pharmacological toolbox. 
 1.3.6.1.1 Structure 
A single gene encodes PDE5A, with three splice variants reported so far (PDE5A1-A3). The 
variation lies in the length of N-termini but function does not seems to be altered (Loughney et 
al., 1998; Nagendran et al., 2007). PDE5A1 and PDE5A2 are expressed in several tissues such 
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as platelets, VSMCs, skeletal muscle, heart, kidney, lung, and brain, whilst PDE5A3 expression 
is restricted to VSMCs (Bender & Beavo, 2006).  
 
 
 
 
  
Figure 1.5 - Structural similarities between PDE5 and PDE6, a) Organization of domains in 
PDE5 and PDE6. b) 3-D surface representation of PDE5 and PDE6 holoenzymes (adapted 
from Cote, 2004) 
 
PDE5 affinity for cGMP is essentially determined by two highly homologous GAF domains 
(GAF-A and GAF-B) with a 100-Fold higher selectivity for cGMP over cAMP (Zoraghi et al., 
2005)  (Fig. 1.5).  High affinity binding of cGMP to GAF-A domain evokes PDE5 
conformational change in the C-terminal tails, initiating the catalytic activity towards cGMP 
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(Castro et al., 2010). PDE5 affinity for cGMP can also be modulated by phosphorylation of the 
enzyme. 
According to this peculiar property (cGMP hydrolyzation induced by cGMP activation of the 
enzyme), PDE5 is essentially playing a role as a negative feedback switch. cGMP signals are 
then generally transient despite continuous addition of NO, as with the use of NO donors 
(Koesling et al., 2005). 
1.3.6.1.1 Pharmacology 
The first selective PDE5 inhibitor developed was Zaprinast. However, the initial PDE5 
inhibitor commercially available was Sildenafil, a false substrate for PDE5, with a significantly 
higher (10-Fold) binding affinity compared to cGMP (Kass, 2012). The main side-effect 
reported for the use of Sildenafil and other PDE5 inhibitors to treat erectile dysfunction is visual 
disturbance. This non-vascular effect is due to cross-reactivity with PDE6, a strongly 
homologous PDE expressed in retinal cells. Other PDE5 inhibitors were then developed with 
a stronger selectivity for PDE5 over PDE6, such as Tadalafil (1020-fold) (Y. Y. Huang et al., 
2013). However, the molecular mechanism responsible for drug selectivity towards PDE5 vs. 
PDE6 remains to be established and might require the elucidation of PDE6 crystal structure. 
1.3.6.2 PDE6 
Also called the “photoreceptor PDE”, PDE6 has been initially characterized as a critical step 
in light transduction in photoreceptors only. Later work reported expression of PDE6 in pineal 
gland (Morin et al., 2001). The role of PDE6 in retina has been evidenced by the identification 
of PDE6 mutation as causal to stationary night blindness, making PDE6 the first PDE known 
to cause a disease secondary to its mutation (Bender & Beavo, 2006). 
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1.3.6.2.1 Structure 
In rod photoreceptors, PDE6 is found in dimer of PDE6α (PDE6A) and a PDE6β (PDE6B) 
subunit. Similarly to PDE5, PDE6 has a catalytic domain in the C-termini with an elevated 
cGMP-specificity. The N-termini contains two GAF domains (GAF-A and GAF-B) with a 
cGMP-binging site in GAF-A (Fig. 1.5). Catalytic efficiency of PDE6 is the highest of all 
known PDEs. When fully activated, PDE6 catalytic rate is impressive with >2000 
µmol/min/mg of cGMP (Gillespie & Beavo, 1988; Cote, 2004; Bender & Beavo, 2006).  
Interestingly, PDE6 heterodimerization does not seem to be essential as heterodimers were not 
detected in avian pineal glands (Morin et al., 2001) or retina of chicken ( Huang et al., 2004; 
Bender & Beavo, 2006). 
In retina, PDE6 is basically responsible for fast hydrolysis of cGMP following light 
stimulation, causing closure of cGMP-gated channels and thus membrane hyperpolarization 
(Ames et al., 1986), therein triggering photoreceptor activation (Cote, 2004). PDE6A and 
PDE6B are expressed in rod cells, while PDE6C (also called PDE6α) are expressed in cone 
cells of the retina.  On the other hand, PDE6 γ and δ isoforms have also been described but 
they both lack catalytic properties. Alternatively, they are considered as inhibitory subunits of 
catalytically active PDE6 isoforms. PDE6 that are expressed in rod cells is composed of two 
large subunits (≈99 kDa) which are the α and β catalytic subunits which are encoded by PDE6A 
and PDE6B genes respectively. It also has two small subunits; the first one (≈ 11 kDa) is 
encoded by PDE6G, the second one (≈ 17 kDa), is a δ regulatory subunit that is encoded by 
PDE6D. On the other hand, PDE6 in cones is composed of two α’ catalytic subunits encoded 
by PDE6C and two inhibitory γ subunits encoded by PDE6H (Francis et al., 2011).  
Until recently, PDE6 expression was considered to be restricted to retinal cone and rod cells 
(Miki et al., 1975) and pineal gland (Morin et al., 2001). However, PDE6 expression has 
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recently been reported in mouse lung (Tate et al., 2002; Nikolova et al., 2010) and in cultured 
cell lines such as HEK293 cells (Wan et al., 2001), melanoma cells lines (Bazhin et al., 2010). 
  
1.3.6.2.1 Activation and pharmacology 
In dark condition, retinal cGMP levels are extremely high (≈ 70 μM) as PDE6 is in an inactive 
form. cGMP activate cGMP-gated cation channels, inducing depolarization. When retina is 
exposed to light, PDE6 triggers a cascade following photon activation of Transducin, a G-
protein. Rod and cone photopigments absorb photons leading to activation of Transducin. 
Activated transducin removes inhibitory influence of PDE6γ and allows catalytic PDE6 to 
hydrolyze cGMP, leading to deactivation of cGMP-gated cation channels at the photoreceptor 
membrane. The PDE6-evoked hyperpolarization then initiates neuronal photoreceptor 
response (Arshavsky et al., 2002).  
Presence of PDE6 in tissues other than retina suggests potential alternative and photon-
independent mechanisms for PDE6 activation. Unfortunately, there are currently no specific 
PDE6 inhibitors commercially available. PDE6 pharmacology mostly overlaps with PDE5. As 
indicated above, visual side effects reported in patients using PDE5 inhibitors for erectile 
dysfunction are due to PDE6 inhibition. 
 
1.3.6.3 Comparison between PDE5 and PDE6 
From a structural perspective, PDE5 and PDE6 share high degree of similarity in terms of 
pharmacological and substrate specificity. Indeed, the amino acid sequence of catalytic domain 
and three-dimensional structure of catalytic domains of both subunits are similar (Fig.1. 5).  
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However, PDE5 and PDE6 are distinct in respect to their enzymatic characteristics. For 
example, maximal cGMP-hydrolysis rate is significantly higher for PDE6 (6000 to 8000 
cGMP/s) compared to PDE5 (three orders of magnitude lower) (D'Amours & Cote, 1999; 
Thomas et al., 1990). Also, activation of PDE6 essentially requires inhibition of the interaction 
with PDE6γ subunits and is therefore constitutively active unless inhibited by PDE6γ. On the 
other hand, PDE5 activation is dependent on binding of cGMP to GAF domains or 
phosphorylation of catalytic domains (Corbin et al., 2000; Cote, 2004). 
1.4 Mathematical models 
NO has been extensively studied over the last decades, and is a key signaling molecule in many 
physiological functions, including the microcirculatory tone. In vivo, NO-cGMP-PDE pathway 
is a complex process and the detailed pathway is yet to be fully quantified and analyzed. The 
use of mathematical models is an interesting approach that can provide valuable insights for 
the physiological role of NO. For example, mathematical models have highlighted the impact 
of the cellular components in the NO/cGMP pathway, and clarified NO signaling and transport 
(Tsoukias, 2008). 
In 1994, two independent groups (Lancaster, 1994; Wood & Garthwaite, 1994) created the first 
mathematical models to study NO biotransport in VSMC.  The model parameters were based 
on available data obtained from the published literature. To date, all the published models 
investigated the NO/cGMP pathway in VSMC despite the fact that the NO/cGMP pathway is 
also present in endothelial cells. In general, simulation models are usually considering 
experimental conditions with a temperature of 20°C, where NO is used to initiate the cGMP 
pathway, and with a homogeneous intracellular distribution of sGC as well as PDE5. sGC is 
included as a generator of cGMP in response to NO, and PDEs is included as a catalyst for 
cGMP hydrolysis. 
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 Mathematical models showed that Hb scavenge significant amounts of NO, but vasodilation 
is maintained, suggesting that either some NO escapes from scavenging or a carrier molecule 
transports NO to VSMC and prevents its scavenging by Hb. More recent studies used different 
geometries and NO transport models based on a continuum approach and standard mass 
transport equations. (Butler et al., 1998; Vaughn et al., 1998). These approaches coupled to 
hydrodynamic modeling showing the existence of a layer free of red blood cells next to the 
endothelium indicated significant NO scavenging rate. 
A recent study reports that NOS activity is the dominant parameter controlling NO release 
(Jiang & George, 2011). As such, modeling the impact of enhanced arginase activity showed 
little impact of l-arginine bioavailability for NOS activity in lung epithelial cells. More 
recently, intracellular signaling and interaction of sGC, NO and PDE5 was shown to modulate 
cGMP levels within the smooth muscle cells (Yang et al., 2005). The presence of multiple 
PDEs and their specific distribution within the endothelial cells could be integrated in such a 
modeling approach and might depict the actual cellular physiological system with an improved 
accuracy. 
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Chapter 2. Objectives of research 
2.1 Rationale 
NO pathway is a fundamental endothelial mechanism regulating smooth muscle contraction 
and vascular tone. In endothelial cells, Ca2+-calmodulin complex activates NOS3 and the NO 
then generated diffuses to the VSMCs. In myocytes, activation of sGC by NO leads to an 
increase in cGMP levels and ultimately evokes muscle relaxation and vasodilation. ECs, as 
major modulator of vascular diameter, are generating colossal amount of NO to modulate 
smooth muscle tone. On the other hand, pharmacological inhibition of cGMP degradation by 
PDE5 is also an efficient way to induce vasodilation.  
Although the NO-sGC-cGMP-PDE pathway has been extensively studied in VSMCs, the 
current understanding of this pathway is ECs is unfortunately limited, despite NO production 
occurring within these cells. The main hypothesis of this study was that phosphodiesterases in 
native endothelium allows a strict control of cGMP levels despite NO production. 
2.2 Broader objectives 
• To determine the expression of cGMP-dependent PDE6 isoforms and PDE5 in native 
endothelium. 
• To establish the subcellular distribution of PDE6 isoforms and PDE5 in native 
endothelial cells. 
• To elucidate the impact of heterogeneous intracellular distribution of PDE6 and PDE5 
on cGMP levels with a mathematical model.  
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3.1 Abstract 
Endothelial cells regulate vascular tone partially through the production and release of nitric 
oxide (NO). The NO-cGMP pathway can be finely tuned through modulation of the cGMP 
degradation by phosphodiesterases (PDEs). Despite elevated production of NO by endothelial 
cells (ECs), desensitization of the NO-cGMP pathway does not occur in ECs. Moreover, NO-
cGMP pathway is an important regulator of endothelial permeability. cGMP-specific PDEs 
might therefore be involved in the control of cGMP levels. PDE6, although originally thought 
to be restricted to retina and pineal gland, is the most efficient PDE and could be involved in 
this process, creating thereof cGMP microdomains. PDE6α, PDE6β and PDE5 were found at 
the transcription and protein level in mesenteric arteries from mice. Although PDE5 is 
homogeneously distributed in vascular cells, PDE6α and more prominently PDE6β showed a 
preferential localization in the perinuclear region. Interestingly, PDE6 subunits were not 
detected by in situ immunofluorescence in vascular smooth muscle or HUVEC cultured cells. 
Computer modeling revealed that, in the absence of PDE6 unitary or repetitive NO pulses 
would result in a global rise in cGMP levels ([cGMP]) that could not be abolished by PDE5. 
However, PDE6 presence in the perinuclear region created a [cGMP] gradient with the 
perinuclear region having less cGMP. This study provides the first evidence of the expression 
PDE6 isoforms in native endothelial cells. Moreover, mathematical modeling strongly suggests 
that the specific perinuclear localization of PDE6 subunits has a dramatic impact on cGMP 
levels, creating cGMP microdomains in native endothelium. 
3.2 Introduction 
Vascular tone is critically regulated by dynamic mechanisms originating from the endothelium. 
The well-described nitric oxide (NO) pathway is a major component of the endothelial 
mechanisms controlling vascular smooth muscle contractile state. Upon rise in endothelial 
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intracellular Ca2+, the Ca2+-calmodulin complex activates endothelial nitric oxide synthase 
(NOS3). The NO thus generated from l-arginine diffuses to the underlying vascular smooth 
muscle and activates the soluble guanylate cyclase (sGC) to produce cGMP. Protein kinase G 
activation by cGMP promotes relaxation of the smooth muscle through several pathways 
including activation of BKCa channels and inhibition of IP3R. On the other hand, cGMP levels 
are also controlled through cyclic nucleotide hydrolysis by phosphodiesterases (PDEs). 
Therefore, inhibition of smooth muscle PDEs promotes vasodilation as evidenced with the 
development of drugs such as sildenafil.  
Phosphodiesterases are enzymes that catalyze the hydrolysis of cyclic nucleotides such as 
cGMP and cAMP into GMP and AMP, respectively. Up to now, 11 families of PDEs have 
been identified in mammals(2, 9). PDEs are sorted based on their specificity toward cGMP or 
cAMP.  PDE1, PDE5, PDE6 and PDE9 are cGMP-specific phosphodiesterases. Interestingly, 
PDE6 is the most efficient cGMP-specific phosphodiesterase. Indeed, despite a slightly lower 
affinity for cGMP in comparison to PDE5, PDE6 has the highest catalytic efficiency of all 
PDEs, with a hydrolysis rate of 3000 cGMP/sec for each PDE6 enzyme. This characteristic is 
highly desired for the initiation of the photoreceptor activation in the retina and has been 
extensively studied(3).  Conversely, such prominent catalytic efficiency could also be 
beneficial in limiting desensitization of the signalling pathway in endothelial cells, which are 
producing important amounts of NO. However, PDE6 is generally considered as a retina-
specific PDE since its expression was thought to be restricted to retina and pineal gland(2). 
Recent evidences suggest that PDE6 expression might not be restricted to these tissues but 
might also be expressed in melanoma cells and in the lung(1, 11). 
Although the NO-cGMP-PDEs pathway has been extensively studied in vascular smooth 
muscle cells and despite the fact that endothelium constitutively generate significant amount 
of NO, the understanding of this pathway in endothelial cells is limited, Moreover, 
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investigations of endothelial NO signalling pathway generally focussed on the modulation of 
endothelial permeability (4, 14). With respect to the growing interest on cyclic nucleotide 
microdomains(5, 6, 13), endothelial cGMP-specific PDEs and their potential impact on the 
generation of cGMP microdomains were investigated. PDE6 regulation of cGMP 
microdomains in endothelial cells was then dynamically studied in relation to endothelial NO 
production with a mathematical model. 
3.3 Materials and methods 
Tissue preparation: 
Mesenteric arteries (3rd and 4th order) were harvested from C57BL/6 mice (3 - 4 months old) 
and cleaned from connective tissue in cooled HEPES solution. All animal manipulations were 
approved by the Montreal Heart Institute Research Center Animal Deontology Committee. 
Immunohistochemistry: 
Mesenteric arteries were cut open and pinned on a sylgard block with the endothelium facing 
up. Arteries were then fixed with paraformaldehyde 4% (20 min) then permeabilized with 0.2% 
triton x-100 and blocked with 4% normal donkey serum (60 min). The arteries were first 
incubated overnight at 4°C with primary antibodies (Table 1).  Arteries were subsequently 
washed with PBS and incubated (60 min) with donkey anti-rabbit ALEXA 555 (dilution 
1/1000) fluorescent antibody. Incubation with DAPI (5 min, 300 nM) was used to reveal the 
nucleus. Immunofluorescence was collected using a Zeiss LSM 510 system confocal 
microscopy (63x oil objective, numerical aperture 1.4, excitation laser wavelength: 488 nm, 
543 nm and 405 nm). All images were deconvolved with Huygens Professional software and 
reconstructed with Zen 2009 light edition with experimental PSFs.  
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Table 3.1: Primary antibodies used for immunohistochemistry 
Target Protein Host Company Catalog number Dilution 
PDE5 Rabbit Santa Cruz SC-32884 1/100 
PDE6α Rabbit Abcam Ab5659 1/100 
PDE6β Rabbit Abcam Ab5663 1/100 
PDE6γ Rabbit Abcam Ab14627 1/100 
 
RNA extraction and real time PCR: 
RNA from whole mesenteric arteries (n=3, for each PDE) was extracted using Qiagen 
columns (RNEasy micro kit) and cDNA was prepared using iScript cDNA synthesis kit (Bio-
Rad). Real time PCR was made with iTaq fast SYBR Green with ROX (Bio-Rad) according 
to the manufacturer’s protocol with a MX3005 thermocycler (Stratagen). Specific primers 
were designed for PDE5, PDE6α and PDE6β. Real time PCR end-products were migrated on 
a 3% agarose gel.  The following primers sequence were used: PDE5: FWD 5’-
AGTCATAGGCGTCTGCCAACTT-3’, REV 5’-CTCTCCACCGCTTCATACATCT-3’; 
PDE6α: FWD 5’-CCACAGACCTTGCCTTGTAT-3’, REV 5’-
CTGCTCCAGCATCATGTACT-3’; PDE6β: FWD 5’-
ACCTCCACAACTGTGAGACACGC-3’, REV 5’- 
GATGTCTGTCAGCTCTTCAAACACCTT-3’. 
Protein extraction: 
Mesenteric arteries immersed in ice-cooled acetone (10% trichloroacetic acid, 10 mM DTT) 
were lyophilized and heated at 95°C for 10 minutes in SDS-gel sample buffer (60 mM Tris-
HCl, pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue, 0.1 M DTT) (8, 15) The 
sample was then placed on a rotator at 4°C overnight. Proteins from the control tissue were 
isolated through enzymatic digestion with/without triton X-100. 
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PDE6a (control tissue, n=4), (mesentric artery, n=3), P=***0.001 
PDE6b (control tissue, n=3), (mesentric artery, n=3), P=*0.05 
PDE5 (control tissue, n=3), (mesentric artery, n=3), P=*0.05 
Unpaired t-test was done to determine if there was a significant difference between control 
and mesenteric tissues. 
Western blot: 
Proteins were migrated on 10% polyacrylamide gel and then transferred to a nitrocellulose 
membrane (100 V, 90 minutes). Protein detection was observed after incubation overnight 
with primary antibody (see table 1) and a HRP-conjugated secondary antibody. Detection 
was obtained using western lightning Plus-ECL (Perkin Elmer). 
Mathematical model: 
The mathematical model is based on a reaction-diffusion equation for cGMP:  
  
where R is the chemical reaction for cGMP creation and D = 130 μm2/s . As proposed in (17), 
the presence of GTP is assumed to be abundant for cGMP production such that the kinetics is 
mainly dependent on the guanylate cyclase concentration. The reaction term is thus given by: 
  
where Vmax,GC = 1.26 μM/s, Km,pde5 = 3.0 μM, vpde5 =  0.0695 s-1, Km,pde6 = 15.0 μM, vpde6 = 
71.35 s-1 (17)}. Parameters for PDE6 isoforms are derived from table I of ref.  (2) and represents 
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the PDE6 α and β isoforms. M(x,y) is the perinuclear spatial distribution of PDE6 isoform and 
is set as a thin annulus with thickness of 0.356 µm. E5c is the activated proportion of GC bound 
to NO, which is given by a simplified set of ordinary differential equations derived from (17) 
assuming: 
  
where k1 = 2.0 nM-1 s-1, k-1 = 100 s-1, k2 = 0.2 s-1, k3 = 0.003 nM-1 s-1, and k4 = 0.4 s-1. The 
spatial 2D domain of the cell is based on a real endothelial cell morphology taken from a 
confocal image (see immunohistochemistry section). 
Together with NO scavenging, the total NO consumption rate may be approximated as a first-
order kinetics (17) such that the fast reaction diffusion equation for [NO] is given by:  
  
where NO consumption rate constant kdno = 0.01 s-1. For the simulations presented here, JNO = 
0.015 nM/s was used to get a steady state [NO] = 1.5 nM yielding a constant [cGMP] = 1 
μM. The diffusion coefficient for NO was set to DNO = 9600 μm2/s (7). 
Numerical method: 
The reaction-diffusion is discretized in space using a centred finite difference method with 
Δx=Δy= 0.178 μm and no-flux boundary conditions at the cell and nucleus borders for both NO 
and cGMP PDEs. The explicit fourth-order Runge-Kutta integration scheme was used for time 
integration of the model. The method was implemented in Matlab v. 7.11.  
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Simulations: 
Two sets of simulation have been calculated. The first set corresponds to a homogeneous 
addition of 220 nM of NO. The second set corresponds to pulsatile addition of NO localized to 
a sub-region of the cell. In both cases, simulations were done with and without perinuclear 
PDE6 to compare its impact on spatial-temporal [cGMP].  
3.4 Results 
Expression of PDE5 and PDE6 subunits in mesenteric arteries 
Expression of PDE5, PDE6α and PDE6β was first sought by RT-PCR in mesenteric arteries 
from mice. Presence of PDE5, PDE6α and PDE6β were detected at the transcription levels as 
shown in Figure 3.1A. Moreover, transcripts for PDE5, PDE6α and PDE6β were detected in 
freshly isolated endothelial cells. Accordingly, Western blotting revealed the presence of PDE5 
in mesenteric arteries from mice. Using specific antibodies, both PDE6 subunits were also 
detected at the protein level in mesenteric arteries from mouse (Figure 3.1B). PDE6γ protein, 
the inhibitory subunit was also detected in mesenteric arteries by immunofluorescence (Figure 
3.2 D). In agreement with the literature, these findings suggest that native endothelial cells 
express PDE5. This data also strongly support the hypothesis that PDE6 subunits are expressed 
in endothelial cells. 
Intracellular distribution of PDE5 and PDE6 subunits 
Microdomains result from a specific subcellular targeting of components of the signalling 
pathway involved. The intracellular distribution of PDE5 and PDE6 subunits was then studied 
to identify potential players in the control of cGMP microdomains. Using the specific 
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antibodies identified in Figure 3.1, a homogeneous distribution of PDE5 was found in in situ 
endothelium (Figure 3.2A). Figure 3.2A, B shows that PDE5 is also homogeneously 
distributed in the underlying smooth muscle cells. HUVEC cultured cells appears to express 
PDE5. On the other hand, PDE6α protein was not detected in smooth muscle layers and a faint 
signal was barely detectable in HUVEC. In native endothelial cells, PDE6α was found in 
aggregates, with preferential localization around the nucleus. Similarly, fluorescence 
associated with PDE6β was not detected in smooth muscle layers or in HUVEC cells. In panels 
i from Figure 3.2, endothelial cells border is evidenced by PECAM-targeted antibody (purple) 
and nuclear membrane is shown by anti-lamin antibody (blue). Perinuclear staining was 
stronger for PDE6β with little if any cytoplasmic staining in endothelial sheets. This 
heterogeneous distribution of PDE6α and β suggests that PDE6 might be involved in 
controlling cGMP microdomains.  A mathematical model was then developed to dynamically 
assess the impact of this heterogeneous distribution of PDE6 on cGMP microdomains in 
endothelial cells. 
Mathematical modeling of cGMP in a typical endothelial cell 
A spatial 2D endothelial cell model was based on an image obtained in the 
immunohistochemistry experiments described above to increase the accuracy of the computer 
modelling. In order to reproduce dynamic control of cGMP levels in physiological conditions, 
NO was used as primary step in the cGMP pathway (Figure 3.3A). In silico model included 
sGC as the generator of cGMP in response to NO and PDEs as catalyst for cGMP hydrolysis. 
Distribution of sGC and PDE5 was established as homogeneous throughout the cell model and 
diffusion of NO and cGMP was also integrated in the model(7). Application of a single NO 
bolus (200 nM) to the entire cell induced a gradual increase in cGMP (11 µM at 45s) throughout 
the cell. As shown in figure 3.3B, cGMP levels gradually decreased in the entire cell with no 
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apparent cGMP microdomains. However, addition of perinuclear PDE6 induced a significant 
modification in the spatial gradient of cGMP. Please note that since enzymatic properties of 
PDE6α and β are highly similar(2), both were considered as one PDE6 to simplify the 
modelling. Beside a fast increase in cGMP levels (2 µM peak at 18 s), perinuclear cGMP never 
reached levels similar to the one found farther from the nucleus (Figure 3.3C and G). Actually, 
the PDE6-dependent difference in cGMP levels between the perinuclear region and distal 
regions is important as illustrated in figure 3.3D (85% lower in cGMP). 
However, NO production is dynamic and may respond to spatially restricted oscillatory Ca2+ 
signals. Therefore, NO application was then modelled as spatially localized pulses (Figure 
3.4). While NO rapidly increased and diffused, the ensuing cGMP cumulated in the endothelial 
cell. A slight gradient in [cGMP] was slowly established throughout the cell in the absence of 
PDE6. Again, inclusion of perinuclear PDE6 in the in silico endothelial cell resulted in a low 
increase in [cGMP] near the nucleus, which only reached 1 µM (Figure 3.4C and F). 
Interestingly, with NO pulses, the [cGMP] gradient was not restricted to the perinuclear region 
(Figure 3.4D). Therefore, [cGMP] modelling with NO pulses shows that despite NO 
distribution reflects normal diffusion pattern, cGMP is significantly lower in the perinuclear 
region in a PDE6-dependent manner. 
3.5  Discussion 
PDEs are important modulators of cellular functions, including vascular tone and endothelial 
permeability(2, 12). Growing body of evidence suggests that cGMP microdomains are tightly 
regulated in several cell types and that these microdomains play essential roles in cellular 
functions(2, 12). 
Interestingly, in vascular smooth muscle cells, we have previously shown that PDE5 is 
sufficient to restrict ANP-induced increase in cGMP to the submembrane region(10). Indeed, 
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application of ANP only increased cGMP near the membrane unless PDE5 was inhibited. In 
such condition, the entire cytoplasm of the vascular myocyte was filled with cGMP. 
Conversely, exposure of myocytes to a NO donor induced a significant increase in cytoplasmic 
cGMP levels despite a functional PDE5. 
PDE6 has been well characterized in retina where it plays an essential role in vision adaptation 
to light(3). Actually, expression of PDE6 was thought to be restricted to the retina and pineal 
gland. However, recent work from Nikolova and colleagues shed light to PDE6 expression in 
other cell types(11). Indeed, their work in lung suggested the functional expression of PDE6 
outside of the retina and pineal gland and its alteration in pathological conditions. Recent work 
also suggested expression of PDE6 in melanoma cell lines(1). 
However, the available pharmacology does not discriminate between PDE5 and PDE6 and 
therefore proscribes a pharmacological approach to study the role of PDE6 heterogeneous 
distribution in endothelial cells(2). According to our immunofluorescence data, the use of 
culture cells is not an option either as HUVEC cells do not express PDE6 isoforms. Even the 
transfection of cultured cells with PDE6 would not be useful as they lack polarity found in 
native endothelial cell, which is essential to the heterogeneous distribution of proteins such as 
PDE6, is not conserved. Therefore, elucidation of the physiological impact of PDE6-dependent 
cGMP microdomains will require the development of compounds that will specifically target 
PDE6 over PDE5. Nevertheless, our in silico endothelial cell clearly establish that PDE6 has a 
strong influence on local cGMP levels (see Figures 3.3 and 3.4) and is most likely responsible 
for cGMP microdomains formation. 
Several mathematical models have been developed studying nitric oxide pathway in smooth 
muscle cells over the years(16). Our in silico model was therefore developed based on similar 
vascular smooth muscle models. However, these models obviously focussed on PDE5 control 
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of cGMP levels(7). To our knowledge, this is the first computational model expressing PDE6 
influence on cGMP microdomains. Moreover, it strongly suggests that PDE6 is a very 
important regulator of cGMP microdomains and may be an important regulator of endothelial 
function. However, the experimental elucidation of the impact of PDE6 in endothelial cells is 
the purpose of future studies. It remains to evaluate how the simplistic 2D representation 
influences the results close to the nucleus where cell height becomes more important. This 
point may interact with the perinuclei distribution of PDE6. 
This study also brings the interesting question regarding the regulatory mechanisms of PDE6 
in endothelial cells. In retina, photon-excitation of transducin results in the activation of PDE6 
catalytic subunits through the relief of the inhibitory influence of PDE6γ. PDE6γ was detected 
in native endothelium and our immunohistochemistry data suggested a diffuse intracellular 
distribution. PDE6γ might therefore be involved in the negative regulation of cGMP hydrolysis 
by PDE6α and β. However, it seems obvious that other mechanisms than photon-activated 
transducin is necessary to regulate endothelial PDE6 and identification of such mechanisms 
will require further investigation. 
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3.7 Figures 
 
 
Figure 3.1. mRNA and protein expression of PDE5, PDE6α and PDE6β in mesenteric 
arteries from mice.   
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Figure 3.2. Intracellular distribution of PDE5, PDE6α and PDE6β in mesenteric arteries 
(MA) from mice and HUVEC cells.   
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Figure 3.3. Simulation results of the cGMP distribution in a typical endothelial cell 
following application of a cell-wide bolus of NO (200 nM).  
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Figure 3.4. Simulation results of the cGMP distribution in a typical endothelial cell 
following spatially localized NO pulses.  
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3.8 Figure legends 
 
Figure 3.1. mRNA and protein expression of PDE5, PDE6α and PDE6β in mesenteric arteries 
from mice.  A. Amplicons were migrated on a 3% agarose gel. mRNA templates were isolated 
from mesenteric arteries of C57/BL6 mice. B. Protein migration on 10% gel in control tissue, 
which is aorta for PDE5 and retina for PDE6,  (left lane and black column) and mesenteric 
arteries (right lane and white column) for PDE5 (a, b), PDE6α (c, d) and PDE6β (e, f). 
Expression of PDEs is normalized to actin expression levels.  
 
Figure 3.2. Intracellular distribution of PDE5, PDE6α and PDE6β in mesenteric arteries (MA) 
from mice and HUVEC cells.  Intracellular localization of PDE5 (Aa), PDE6α (Ba) and 
PDE6β (Ca) (red) in endothelium and smooth muscle (Ab, Bb, Cb) of cut-open mesenteric 
arteries.  PDE5 (Ac), PDE6α (Bc) and PDE6β (Cc) distribution in HUVEC cells (right 
column). Staining of the nucleus with DAPI is shown in blue except in panels i. In panels i, 
antibodies targeting PECAM (purple) and lamin (blue) show endothelial cell plasma and 
nuclear membrane, respectively.  Scale bar = 10 µm. 
 
Figure 3.3. Simulation results of the cGMP distribution in a typical endothelial cell following 
application of a cell-wide bolus of NO (200 nM). A. Homogeneous decrease of [NO] over time 
as depicted by the superimposed curves obtained at three different positions in the cell 
(positions are shown by the X, o, and Δ markers in panel E). B. Simulation without PDE6: 
Intracellular [cGMP] for the same three positions exhibiting a biphasic variation with an initial 
increase in the concentration peaking at ~45 s followed by a decrease. C. Same as in B but with 
the presence of peri-nuclear PDE6 D. Difference in [cGMP] between positions x and Δ (x - Δ) 
and positions x and o (x - o) with (green curves) and without (blue curves) perinuclear PDE6. 
E. Uniform spatial [NO]≈134.9 nM at t=50 s. F. Uniform [cGMP] ≈11.3 µM at t=50 s in 
absence of PDE6. G. Spatial distribution of [cGMP] with perinuclear PDE6 obtained at t=50 s 
clearly showing the quenching effect of PDE6 on local [cGMP]. All simulations were carried 
out with a homogeneous distribution of PDE5. 
Figure 3.4. Simulation results of the cGMP distribution in a typical endothelial cell following 
spatially localized NO pulses. A. Increase of [NO] by repetitive pulses (10 s periods) where 
220 nM of NO is added in the region defined by the dashed circle (in panel E). NO diffusion 
within the cell dampens NO oscillations after each pulse with an incremental distance from the 
source as highlighted by the reduced variations from the x position (closest to the source, panel 
E) to the Δ position (furthest from the source). B. Traces of [cGMP] obtained without PDE6 at 
the same three positions showing higher [cGMP] close to the source (position x) and lower 
[cGMP] far from the NO source (position Δ). C. Same as in panel B but for a simulation 
obtained with perinuclear PDE6. D. Difference in [cGMP] between positions x and Δ (x - Δ) 
and positions x and o (x - o) with (green curves) and without (blue curves) perinuclear PDE6. 
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E. Spatial distribution of [NO] at t = 50 s showing a clear [NO] gradient within the cell with 
lower concentration far from the NO source. F. Spatial distribution of [cGMP] at t = 50 s 
obtained without perinuclear PDE6. G. Same as panel F but with perinuclear PDE6 quenching 
the [cGMP]. All simulations were carried out with a homogeneous distribution of PDE5. 
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Chapter 4. Discussion 
Endothelium is a major regulator of vascular homeostatsis, including blood pressure via 
modulation of arterial diameter. Amongst numerous mechanisms, ECs generate and release 
NO to evoke VSMCs relaxation and vasodilation. In VSMCs, NO triggers the sGC-cGMP 
pathway leading to a decreased muscular tone. However, despite the fact that NO is produced 
in ECs and most likely activates endothelial signalling, very little information is available on 
the sGC-cGMP pathway in ECs. The appropriate machinery for cGMP production and its 
effector (PKG) has been reported in ECs. One could then ask how this system remains 
functional and below saturation. The work from this thesis provides the first evidence of 
intracellular organization allowing generation of subcellular cGMP microdomains in native 
endothelial cells.  
Dynamic microdomains of cGMP have been reported and seem to be involved in regulation of 
cellular functions in other cell types. Nausch and co-workers reported that ANP-induced 
increase in cGMP is regulated by PDE5 in VSMCs. ANP activation of pGC increases cGMP 
in VSMCs but this increase is restricted to sub membrane space. Indeed, unless PDE5 is 
inhibited, cytoplasmic cGMP levels will remain low except in close proximity of the plasma 
membrane. However, inhibition of PDE5 allows a global increase in cytoplasmic cGMP levels 
in response to ANP. Similar control of cGMP levels was not found when cGMP was increased 
with NO donors. This established PDE5 as a major regulator of cGMP microdomains in native 
VSMCs (Nausch et al., 2008). Our work is consistent with this study, suggesting that PDE6 in 
the near nuclear space would regulate local cGMP levels even in the presence of NO and 
functional sGC. However, our simulation did not provide evidence of PDE5-dependent cGMP 
microdomains in native ECs. 
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The elevated efficiency in cGMP hydrolysis by PDE6 is a coveted property for an endothelial 
PDE. Indeed, a highly efficient degradation of cGMP is required to maintain cytoplasmic levels 
in the low range despite the production of NO by ECs. However, the initial preliminary 
evidence of PDE6 expression in ECs were unexpected, especially since PDE6 expression was 
thought to be restricted to retina and pineal gland until recently (Nikolova et al., 2010; Bazhin 
et al., 2010; Morin et al., 2001). Our work provides the first evidence of endothelial expression 
of PDE6 and establishes the enzyme as a key regulator of endothelial cGMP. Interestingly, 
cultured endothelial cell lines are not expressing PDE6 isoforms, suggesting that loss of PDE6 
expression is part of the phenotype alteration induced by cell culture processes. Moreover, 
PDE5 and PDE6 have distinct subcellular targeting in native endothelial cells. The relative 
catalytic properties of individual PDE isoforms, in addition to their intracellular distribution, 
would reflect distinct roles in modulation of endothelial functions. A current challenge in this 
field is the overlap of pharmacology targeting PDE5 and PDE6, therefore making it difficult to 
dissect the distinct roles of each isoenzyme. 
In this work, we found the expression of PDE5, PDE6α and PDE6β at the transcription levels 
(using RT-PCR) as well as at translation levels (using Western blot) in mesenteric arteries from 
mice. PDE6γ protein was also detected in mesenteric arteries by immunofluorescence. These 
findings confirm the presence of PDE5 in native endothelium and sustain the hypothesis that 
PDE6 subunits are expressed in endothelial cells. As the intracellular distribution of PDE5 and 
PDE6 subunits is responsible for creation of cGMP microdomains at certain intracellular areas, 
immunofluorescence studies, by using specific antibodies, were used. A homogeneous 
distribution of PDE5 was seen in endothelium and in the underlying smooth muscle cells and 
in HUVEC cells, while PDE6α protein was detected in native endothelial cells, in aggregates 
around the nucleus, but the fluorescence associated with PDE6α was not detected in smooth 
muscle cells, and it was barely detectable in HUVEC cells. Likewise, fluorescence associated 
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with PDE6β was detected in native endothelial, but not in smooth muscle or HUVEC cells. 
The heterogeneous distribution of PDE6α and β support the hypothesis that PDE6 might be 
involved in controlling cGMP microdomains. 
In silico studies that mimick in vivo NO diffusion and biodistribution have been developed 
over the years (Tsoukias, 2008). Even though, the mathematical representation used in our 
simulations is the first computational model studying the influence of combined PDE5/PDE6 
on cGMP in endothelial cells, it has been developed based on an approach used to study the 
effect of PDE5 on cGMP in vascular smooth muscle cells (Yang et al., 2005). Our mathematical 
approach has been used to look at two different aspects of intracellular cGMP. Firstly, it is the 
first model studying the role of local NO in endothelial cGMP formation. Secondly, the models 
suggest how specific intracellular distribution of PDE6 can be an important regulator of cGMP 
microdomains. Further development of the model would involve the simulation of more 
physiological conditions, where NO production is linked to endothelial intracellular Ca2+ 
dynamics including time-dependent changes. Indeed, oscillatory Ca2+ signals could result in 
oscillatory NO production with correlating (but not identical) kinetics. Indeed, the timescale of 
processes leading to cGMP levels are relatively small and therefore imply frequency-dependent 
memory effects and variations in cGMP oscillation frequency and amplitude.  
However, the actual function of these microdomains remains to be elucidated, but it can be 
hypothesized that low perinuclear cGMP levels might be involved in control of nuclear 
transport or receptor activity found at the nuclear membrane. Interestingly, expression of PDE6 
appears to be absent from cultured endothelial cells. It is thus tempting to postulate that PDE6 
expression could be involved in regulation of gene expression or even endothelial cell 
proliferation. This hypothesis will be evaluated in future studies. A contribution of these cGMP 
microdomains in regulation of endothelial permeability also remains to be established. 
50 
 
The activation mechanism of PDE6 in native endothelial cells is also unclear. Indeed, in retina, 
PDE6 is activated following photon activation of transducin, which removes PDE6γ inhibition. 
Since it appears unlikely that photons would be the initial activation step in arteries, different 
regulatory processes are probably involved and will necessitate further investigation. 
Despite its significant relevance, physiological impact of PDE6 in endothelium has not been 
addressed in this study. The pharmacological tools currently available do not allow a clear 
specific assessment of the effect of PDE6 inhibition on cellular function. Moreover, our 
immunofluorescence data showed the lack of PDe6 isoforms in HUVEC cells. Therefore, 
investigation of endothelial PDE6 essentially relies on native tissue, limiting molecular biology 
approaches aiming at an alteration of PDE6 isoform expression. The use of whole arteries is 
also a limiting factor as smooth muscle cells are inevitably present, with a working NO-cGMP-
PDE5 pathway.  
The use of a mathematical model to simulate cGMP levels in endothelial cells is a very 
powerful approach. However, such approach unfortunately relies on assomptions that might 
affect simulations outcomes. Indeed, the current model consider a 2D endothelial cell although 
three dimensional cells could have a different propagation/localization pattern of the 
moleculaes considered. Also, for the sake of simplification, other partners in the NO-cGMP 
pathway were ignored in this first iteration, including other PDE isoforms.  
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Chapter 5. Conclusion 
The NO‐cGMP pathway is an essential modulator of several vascular functions. PDEs are 
crucial molecular regulators of this signalling pathway. However, the endothelial pendant of 
the NO-cGMP-PDE pathway is poorly understood. In addition to PDE5, this study established 
the expression of PDE6, a cGMP-specific PDE that was initially thought to be restricted to the 
retina, in native endothelial cells. All known PDE6 isoforms were detected both at mRNA and 
protein levels in native endothelial cells from resistance arteries. Interestingly, signals 
associated with PDE6 expression were not detected in cultured endothelial cell lines.  
Moreover, peculiar PDE6α and β intracellular localization near the nuclear membrane suggests 
a potential involvment in the generation and sustainment of cGMP microdomains. Since PDE5 
is found homogenously distributed in the native cells, roles for PDE5 and PDE6 is most likely 
distinct.  
The computational model applied on endothelial cells showed that in the absence of PDE6, 
repetitive or single NO pulses cause a global intracellular increase in cGMP levels, which 
cannot be efficiently controlled by PDE5. However, the presence of PDE6 surrounding nuclei 
creates a perinuclear zone with lower cGMP levels (cGMP microdomains), suggesting a 
possible functional role for the enzyme within the perinuclear region in native endothelium. 
Elucidated presence of the highly potent PDE6 in multifunctional cells such as endothelial 
cells, now warrants further investigations to explore the physiological role of cGMP 
microdomains. Future studies will evaluate the hypothesis that PDE6 expression could be 
involved in regulation of gene expression and endothelial cell proliferation as well as the 
possibility of its impact in mechanisms of permeability.. Moreover, further understanding of 
PDE6 regulatory mechanisms in endothelial cells would also be relevant to the development 
of potential pharmacological tools. 
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